At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Timolol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blinded, Placebo-Controlled, Cross Over Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine
In Brief
A Phase 2 clinical trial evaluating Timolol and Placebo for Migraine. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the efficacy (headache freedom at 2 hours) of Timolol 0.5% ophthalmic solution compared to placebo in acute treatment of migraine headache. And to assess the safety and tolerability of Timolol 0.5% ophthalmic solution in treatment of acute migraine headache.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartFeb 2017
Primary CompletionApr 2018
First PostedFeb 2019
TodayJul 2026
First PostedFeb 11, 2019
Enrollment StartFeb 27, 2017
Primary CompletionApr 14, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.4 years ago
Interventions
Timololdrug
Timolol is a clear solution supplied in a plastic ophthalmic dispenser.
Placebodrug
Placebo is normal saline solution that will be supplied in container matched to Timolol container.